21st Aug 2020 10:21
(Alliance News) - Silence Therapeutics PLC on Friday said it has filed a registration statement with the US Securities & Exchange Commission to allow the Nasdaq listing of the company's American depositary shares.
The statement was filed in order to allow for the creation of a trading market in the US for ADSs representing the RNA therapeutics developer's ordinary shares.
Silence, which has its headquarters in London, stressed that is not planning to register and new primary issuance of securities. Its ordinary shares will still be admitted to trading on London's AIM market.
Shares in Silence were down 1.1% at 456.00 pence in London on Friday morning.
By Anna Farley; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
SLN.L